Heineken has urged hospitality businesses across the UK to reconsider portion sizes and menu offerings as GLP-1 weight-loss drugs become more widely available, with the brewer acknowledging that broader consumer uptake of these medications could weigh on demand for beer and cider.
Hospitality businesses received an internal presentation that autumn laying out a case for smaller serving sizes and a broader range of drinks with reduced or no alcohol content. Among the additions put forward was a plan to serve smaller food portions alongside drinks.
According to a broadcast news outlet, the document outlined projections that hospitality venues could experience a drop in both visitor numbers and consumer expenditure as uptake of the medications expands.
Data drawn from Circana's tracking methodology placed American homes containing at least one GLP-1 user alongside homes without any such user across a two-year window stretching from 2024 through 2026, with the findings relayed through a broadcast news outlet. By the two-year mark, the monitored households were directing roughly 7% less toward alcohol overall, with the steepest pullback falling on beer, where outlays dropped around 13.5%.
Heineken UK data covering the twelve months to February 2026 put on-trade beer revenue — drawn from pubs, bars, and restaurants across the country — at close to £14 billion. According to the report, revenue from no- and low-alcohol beer came in under the £300 million mark.
Ten of the eleven GLP-1 users that one broadcast outlet spoke with said they had reduced their alcohol consumption. Reported reactions ranged from physical discomfort and nausea after consuming alcohol to a reduced urge to drink at all.
In its presentation, Heineken drew a connection between the prospect of reduced drink orders and consumers reporting a feeling of fullness. Beverage producers already navigating a contraction in alcohol demand — tied to both health-conscious behaviour and tighter household budgets across certain markets, as industry data has indicated — would face an additional layer of pressure under the proposed change.
A spokesperson for Heineken described the event as part of the brewer's routine outreach to hospitality operators across the UK. The company added that its portfolio is structured to capture appetite for compact serving sizes, reduced-alcohol options, and higher-end selections, while keeping a close watch on how purchasing habits among consumers take shape through 2027.
Rival firms have framed their assessments of the potential fallout in measured, restrained terms. Investors in the beverage corporation were told its day-to-day business would face little disruption even if the trend gained broader traction across the industry.
The brewer's position, relayed to a broadcaster with an established reputation, was that existing data had not yet pointed to those medications as a definitive force behind shifts in beer consumption. No statement was made available from Anheuser-Busch InBev on the matter.
